Castle Biosciences Inc (CSTL) Stock AnalysisCSTLCastle Biosciences Inc

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC). It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Castle Biosciences Inc (CSTL) appears to be a good buy at the current price of $34.42. The company recently reported Q2 2026 revenue of $103.5 million, a significant 20% increase year-over-year, and raised its full-year revenue guidance to between $365 million and $375 million. Additionally, the stock has a gross margin of 74.94% in Q2 2026, showcasing strong profitability potential. However, the main risk is its current negative earnings per share (EPS) of -0.07, indicating ongoing losses that investors should monitor closely.